Pharma BD Deal Intelligence
Berna's vaccines and manufacturing base turned Crucell into a takeover target J&J paid a 58% premium for five years later
Full analysis, sources & comparables →Julius Bar analyst: 'It is the best that could have happened to Berna shareholders. The negative point we'd see in this transaction is the missing cash part.'…
Crucell's CHF 591M offer for Berna at a 20% premium positions the combined company to compete with Novartis/Chiron, Merck, GSK and Sanofi-Aventis as global…
The 2006 combination of Crucell, Berna Biotech, and SBL Vaccines created the sixth-largest vaccine company worldwide; Crucell was acquired by J&J in 2011.
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Vaccines; all-share deal CHF 591M, created leading independent vaccine company
Berna's vaccines and manufacturing base turned Crucell into a takeover target J&J paid a 58% premium for five years later
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Crucell N.V. / Berna Biotech AG (this deal) | 2006 | $450M | 85 |
| Boehringer Ingelheim International GmbH / Sanofi SA (Merial Animal Health) | 2015 | $12.4B | 81 |
| Pfizer Inc. / Baxter International Inc. (commercial vaccines portfolio) | 2014 | $635M | 77 |
| GSK plc / Affinivax Inc. | 2022 | $3.3B | 48 |
| Novavax Inc. / Praha Vaccines | 2020 | $167M | 48 |
| Johnson & Johnson / Crucell N.V. | 2010 | $2.4B | 47 |
| Takeda Pharmaceutical Company Ltd. / Novavax Inc. | 2021 | $350M | — |
← Browse all deals · How we score deals
More: 2006 deals · Vaccines deals